153 related articles for article (PubMed ID: 37339720)
1. A synthetic lethal approach to drug targeting of G-quadruplexes based on CX-5461.
Jin M; Hurley LH; Xu H
Bioorg Med Chem Lett; 2023 Jul; 91():129384. PubMed ID: 37339720
[TBL] [Abstract][Full Text] [Related]
2. A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
Xu H; Hurley LH
Bioorg Med Chem Lett; 2022 Dec; 77():129016. PubMed ID: 36195286
[TBL] [Abstract][Full Text] [Related]
3. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Xu H; Di Antonio M; McKinney S; Mathew V; Ho B; O'Neil NJ; Santos ND; Silvester J; Wei V; Garcia J; Kabeer F; Lai D; Soriano P; Banáth J; Chiu DS; Yap D; Le DD; Ye FB; Zhang A; Thu K; Soong J; Lin SC; Tsai AH; Osako T; Algara T; Saunders DN; Wong J; Xian J; Bally MB; Brenton JD; Brown GW; Shah SP; Cescon D; Mak TW; Caldas C; Stirling PC; Hieter P; Balasubramanian S; Aparicio S
Nat Commun; 2017 Feb; 8():14432. PubMed ID: 28211448
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461.
Masud T; Soong C; Xu H; Biele J; Bjornson S; McKinney S; Aparicio S
Sci Rep; 2021 May; 11(1):9812. PubMed ID: 33963218
[TBL] [Abstract][Full Text] [Related]
5. The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.
Koh GCC; Boushaki S; Zhao SJ; Pregnall AM; Sadiyah F; Badja C; Memari Y; Georgakopoulos-Soares I; Nik-Zainal S
Nat Genet; 2024 Jan; 56(1):23-26. PubMed ID: 38036782
[TBL] [Abstract][Full Text] [Related]
6. G-quadruplex DNA: a novel target for drug design.
Teng FY; Jiang ZZ; Guo M; Tan XZ; Chen F; Xi XG; Xu Y
Cell Mol Life Sci; 2021 Oct; 78(19-20):6557-6583. PubMed ID: 34459951
[TBL] [Abstract][Full Text] [Related]
7. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells.
McLuckie KI; Di Antonio M; Zecchini H; Xian J; Caldas C; Krippendorff BF; Tannahill D; Lowe C; Balasubramanian S
J Am Chem Soc; 2013 Jul; 135(26):9640-3. PubMed ID: 23782415
[TBL] [Abstract][Full Text] [Related]
8. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
[TBL] [Abstract][Full Text] [Related]
9. DNA repair protein RAD52 is required for protecting G-quadruplexes in mammalian cells.
Liu S; Wang Z; Shah SB; Chang CY; Ai M; Nguyen T; Xiang R; Wu X
J Biol Chem; 2023 Jan; 299(1):102770. PubMed ID: 36470428
[TBL] [Abstract][Full Text] [Related]
10. DNA G-Quadruplex in Human Telomeres and Oncogene Promoters: Structures, Functions, and Small Molecule Targeting.
Chen L; Dickerhoff J; Sakai S; Yang D
Acc Chem Res; 2022 Sep; 55(18):2628-2646. PubMed ID: 36054116
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Predisposition Genes and Synthetic Lethality.
Neiger HE; Siegler EL; Shi Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
[No Abstract] [Full Text] [Related]
12. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
13. Tandem application of ligand-based virtual screening and G4-OAS assay to identify novel G-quadruplex-targeting chemotypes.
Musumeci D; Amato J; Zizza P; Platella C; Cosconati S; Cingolani C; Biroccio A; Novellino E; Randazzo A; Giancola C; Pagano B; Montesarchio D
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1341-1352. PubMed ID: 28130159
[TBL] [Abstract][Full Text] [Related]
14. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.
Groelly FJ; Porru M; Zimmer J; Benainous H; De Visser Y; Kosova AA; Di Vito S; Serra V; Ryan A; Leonetti C; Bruna A; Biroccio A; Tarsounas M
EMBO Mol Med; 2022 Mar; 14(3):e14501. PubMed ID: 35107878
[TBL] [Abstract][Full Text] [Related]
16. G-quadruplex in cancer biology and drug discovery.
Nakanishi C; Seimiya H
Biochem Biophys Res Commun; 2020 Oct; 531(1):45-50. PubMed ID: 32312519
[TBL] [Abstract][Full Text] [Related]
17. [Determination of the binding of natural products to the human c-myb oncogene promoter G-quadruplex DNA by capillary electrophoresis and electrospray ionization mass spectrometry].
Wang S; Yang Y; Fan S; Li H; David DYC
Se Pu; 2020 Sep; 38(9):1069-1077. PubMed ID: 34213273
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent Guanidine derivative that selectively binds and stabilizes the human BCL-2 G-quadruplex DNA and downregulates the transcription.
Pandya N; Rani R; Kumar V; Kumar A
Gene; 2023 Jan; 851():146975. PubMed ID: 36261091
[TBL] [Abstract][Full Text] [Related]
19. Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S; Pansa MF; Paviolo NS; Castellaro AM; Andino DL; Nigra AD; García IA; Racca AC; Rodriguez-Berdini L; Angiolini V; Guantay L; Villafañez F; Federico MB; Rodríguez-Baili MC; Caputto BL; Drewes G; Madauss KP; Gloger I; Fernandez E; Gil GA; Bocco JL; Gottifredi V; Soria G
Clin Cancer Res; 2019 Jul; 25(13):4049-4062. PubMed ID: 30890549
[TBL] [Abstract][Full Text] [Related]
20. Assessing G4-Binding Ligands In Vitro and in Cellulo Using Dimeric Carbocyanine Dye Displacement Assay.
Desai N; Shah V; Datta B
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
